Clinical Trial Detail

NCT ID NCT00492505
Title Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors San Diego Pacific Oncology and Hematology Associates
Indications

melanoma

Therapies

Cisplatin + Sorafenib + Tamoxifen

Age Groups: adult

No variant requirements are available.